Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study

Claire S Waddington; W T Walker; C Oeser; A Reiner; T John; S Wilkins; M Casey; P E Eccleston; R J Allen; I Okike; S Ladhani; E Sheasby; K Hoschler; N Andrews; P Waight; A C Collinson; P T Heath; A Finn; S N Faust; M D Snape; E Miller; Andrew Pollard

doi:10.1136/bmj.c2649

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study

Claire S Waddington, W T Walker, C Oeser, A Reiner, T John, S Wilkins, M Casey, P E Eccleston, R J Allen, I Okike, S Ladhani, E Sheasby, K Hoschler, N Andrews, P Waight, A C Collinson, P T Heath, A Finn, S N Faust, M D SnapeE Miller, Andrew Pollard

Research output: Contribution to journal › Article (Academic Journal) › peer-review

Abstract

To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.

Original language	English
Article number	c2649
Journal	BMJ
Volume	340
DOIs	https://doi.org/10.1136/bmj.c2649
Publication status	Published - 27 May 2010

Access to Document

10.1136/bmj.c2649

Fingerprint Dive into the research topics of 'Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study'. Together they form a unique fingerprint.

Cite this

Waddington, C. S., Walker, W. T., Oeser, C., Reiner, A., John, T., Wilkins, S., Casey, M., Eccleston, P. E., Allen, R. J., Okike, I., Ladhani, S., Sheasby, E., Hoschler, K., Andrews, N., Waight, P., Collinson, A. C., Heath, P. T., Finn, A., Faust, S. N., ... Pollard, A. (2010). Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study. BMJ, 340, [c2649]. https://doi.org/10.1136/bmj.c2649

Waddington, Claire S ; Walker, W T ; Oeser, C ; Reiner, A ; John, T ; Wilkins, S ; Casey, M ; Eccleston, P E ; Allen, R J ; Okike, I ; Ladhani, S ; Sheasby, E ; Hoschler, K ; Andrews, N ; Waight, P ; Collinson, A C ; Heath, P T ; Finn, A ; Faust, S N ; Snape, M D ; Miller, E ; Pollard, Andrew. / Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study. In: BMJ. 2010 ; Vol. 340.

@article{2744b081658b4e33b31d6c6c729c819e,

title = "Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study",

abstract = "To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.",

author = "Waddington, {Claire S} and Walker, {W T} and C Oeser and A Reiner and T John and S Wilkins and M Casey and Eccleston, {P E} and Allen, {R J} and I Okike and S Ladhani and E Sheasby and K Hoschler and N Andrews and P Waight and Collinson, {A C} and Heath, {P T} and A Finn and Faust, {S N} and Snape, {M D} and E Miller and Andrew Pollard",

year = "2010",

month = may,

day = "27",

doi = "10.1136/bmj.c2649",

language = "English",

volume = "340",

journal = "BMJ",

issn = "0959-8138",

publisher = "BMJ Publishing Group",

}

Waddington, CS, Walker, WT, Oeser, C, Reiner, A, John, T, Wilkins, S, Casey, M, Eccleston, PE, Allen, RJ, Okike, I, Ladhani, S, Sheasby, E, Hoschler, K, Andrews, N, Waight, P, Collinson, AC, Heath, PT, Finn, A, Faust, SN, Snape, MD, Miller, E & Pollard, A 2010, 'Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study', BMJ, vol. 340, c2649. https://doi.org/10.1136/bmj.c2649

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study. / Waddington, Claire S; Walker, W T; Oeser, C; Reiner, A; John, T; Wilkins, S; Casey, M; Eccleston, P E; Allen, R J; Okike, I; Ladhani, S; Sheasby, E; Hoschler, K; Andrews, N; Waight, P; Collinson, A C; Heath, P T; Finn, A; Faust, S N; Snape, M D; Miller, E; Pollard, Andrew.

In: BMJ, Vol. 340, c2649, 27.05.2010.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

TY - JOUR

T1 - Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study

AU - Waddington, Claire S

AU - Walker, W T

AU - Oeser, C

AU - Reiner, A

AU - John, T

AU - Wilkins, S

AU - Casey, M

AU - Eccleston, P E

AU - Allen, R J

AU - Okike, I

AU - Ladhani, S

AU - Sheasby, E

AU - Hoschler, K

AU - Andrews, N

AU - Waight, P

AU - Collinson, A C

AU - Heath, P T

AU - Finn, A

AU - Faust, S N

AU - Snape, M D

AU - Miller, E

AU - Pollard, Andrew

PY - 2010/5/27

Y1 - 2010/5/27

N2 - To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.

AB - To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-77953933028&partnerID=8YFLogxK

U2 - 10.1136/bmj.c2649

DO - 10.1136/bmj.c2649

M3 - Article (Academic Journal)

C2 - 20508026

VL - 340

JO - BMJ

JF - BMJ

SN - 0959-8138

M1 - c2649

ER -